(Q37091269)

18 August 2017

Treatment results in advanced stage Hodgkin's lymphoma: a retrospective study (English)

1 reference

18 August 2017

H Jain

1

1 reference

18 August 2017

M Sengar

2

1 reference

18 August 2017

R Nair

3

1 reference

18 August 2017

H Menon

4

1 reference

18 August 2017

S Laskar

5

1 reference

18 August 2017

T Shet

6

1 reference

18 August 2017

S Gujral

7

1 reference

18 August 2017

E Sridhar

8

1 reference

18 August 2017

language of work or name

English

0 references

publication date

1 April 2015

1 reference

Journal of Postgraduate Medicine

18 August 2017

1 reference

18 August 2017

61

1 reference

18 August 2017

2

1 reference

18 August 2017

88-91

1 reference

ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned

18 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4943438

Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4943438

ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4943438

Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4943438

Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4943438

High-risk Hodgkin's disease prognostic factors

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4943438

Should poor risk patients with Hodgkin's disease be sorted out for intensive treatments?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4943438

Prognostic factors in advanced Hodgkin's disease: problems and pitfalls. Towards an international prognostic index

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4943438

Clinical course and complications in Hodgkin's disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4943438

Management of Hodgkin's disease in western India

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4943438

Hodgkin's disease (retrospective study of 119 cases)

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4943438

Revised response criteria for malignant lymphoma

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4943438

Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519).

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4943438

Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4943438

Hodgkin's disease: a clinicopathologic study.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4943438

Fixed versus response-adapted MOPP/ABVD chemotherapy in Hodgkin's disease. A prospective randomized trial.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4943438

Long-term follow-up of Hodgkin's disease trial

3 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25766339

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Hodgkin's disease: a retrospective analysis of 15 years experience at a large referral centre

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25766339

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Immunoprofile of Hodgkin's lymphoma in India

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25766339

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.4103/0022-3859.150446

1 reference

18 August 2017

1 reference

18 August 2017

PubMed publication ID

25766339

1 reference